An experimental oral medication Bristol Myers Squibb is developing did better than a placebo at slowing lung function decline for up to 26 weeks, slightly more than six months, in people with idiopathic pulmonary fibrosis (IPF). The effect was seen when the therapy, BMS-986278, was given at a…
Researchers have discovered a variant of the usual basal stem cells found in the lungs that may contribute to scarring, or fibrosis, in people with idiopathic pulmonary fibrosis (IPF) — and which may be a therapeutic target to slow disease progression. The team found that these basal stem cells,…
patientMpower and Qureight have joined forces to accelerate the discovery of new prognostic markers for interstitial lung diseases (ILDs), a group of lung diseases characterized by scarring and inflammation that includes idiopathic pulmonary fibrosis (IPF). The collaboration will harness Qureight’s artificial intelligence (AI) capability along with patientMpower’s…
Dosing is complete in the Phase 3 REBUILD clinical trial testing INOpulse (inhaled nitric oxide) in people with pulmonary fibrosis at risk of developing pulmonary hypertension. In the blinded part of the study, which is now complete, participants were randomly assigned to receive nitric oxide or a placebo administered…
The Pulmonary Fibrosis Foundation (PFF) is urging patients to use only federally approved oxygen delivery devices, as nonprescription supplemental oxygen may be unreliable and cause serious health problems. In a position statement, the organization said that those living with pulmonary fibrosis (PF) and related disorders should stick…
The dynamics of the extracellular matrix (ECM) that surrounds cells and gives structure to tissues may play an important role in the behavior of myofibroblasts, the connective tissue cells that are implicated in pulmonary fibrosis (PF), according to a recent study. “Our results underline the importance of the interactions…
Vyne Therapeutics‘ experimental inhaled therapy VYN201 led to significant reductions in lung fibrosis and improvements in lung function in a mouse model of idiopathic pulmonary fibrosis (IPF), the company announced. “The data from this well-validated preclinical model of IPF clearly demonstrates VYN201’s potential to deliver a potent anti-inflammatory…
A high dose of bexotegrast, an oral treatment being developed by Pliant Therapeutics, continues to be well-tolerated for up to about nine months, with no serious side effects in people with idiopathic pulmonary fibrosis (IPF), according to long-term data from a Phase 2a trial. Six-month data from the…
Innovate UK has awarded biotechnology company Senisca £571,350 (about $712,000) to develop oligonucleotide treatments for idiopathic pulmonary fibrosis (IPF). The UK-based company is working on innovative biologic treatments that use oligonucleotides — short strands of RNA or DNA — to reverse senescence in IPF-specific tissues. Senescence, which…
The first participant has been dosed in a clinical trial testing the experimental anti-fibrotic therapy BBT-877 in people with idiopathic pulmonary fibrosis (IPF). The milestone was announced by BBT-877’s developer Bridge Biotherapeutics, which initiated the trial late last year. “The first patient dosing of BBT-877 marks an…
Get regular updates to your inbox.
